TMDX
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Article Summary
HOLD- TransMedics Group Inc. (NASDAQ: TMDX) is being investigated by Halper Sadeh LLC, an investor rights law firm investigating whether certain officers and directors breached their fiduciary duties to shareholders, with shareholders encouraged to contact the firm to discuss their rights and options at no cost or obligation.
- The firm would handle any matter on a contingent fee basis whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
- Long-term shareholders may be able to seek corporate governance reforms, return of funds back to Transmedics Group, a court-approved financial incentive award, or other relief and benefits.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 30.2% | 25% | 85.0 ptsExcellent (30.2%) - Strong growth |
| EPS Growth Next 5Y ? | -2.4% | 25% | 0.0 ptsNegative (-2.4%) - Declining expectations |
| Target Price Upside ? | 56.2% | 20% | 100.0 ptsMassive Upside (56.2%) - Target: $112.89 vs Current: $72.26 |
| Gross Margin % ? | 58.8% | 15% | 80.0 ptsVery Healthy (58.8%) - High-quality margins |
| Drawdown from 52-Wk High ? | -53.7% | 15% | 100.0 ptsDeep Discount (-53.7%) - Best entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About TMDX
- TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
- The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.
- The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity.
- The company was founded in 1998 and is headquartered in Andover, Massachusetts.